FindTrial
Sign In

Comparasion of two different doses of methylprednisolone with dexamethasone in patients with severe COVID 19 patients .

Effects of two different doses of methylprednisolone versus conventional dose of dexamethasone on recovery in patients with severe COVID 19 infection - A prospective randomised control study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/038317
Enrollment
291
Registered
2021-11-29
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Methylprednisolone,Dexamethasone: Methylprednisolone and dexamethasone belongs to steroid group Intervention2: Methylprednisolone: Methylprednisolone 120 mg for 5 days f/b 60 mg for 3 d

Sponsors

Government medical college
Lead Sponsor
Dr Vijaykumar H N
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-75 yrs 2. Adult patients with RTPCR confirmed. 3. Patients with CT Scan features ( CORAD score4 and above) 4. Patients with severe COVID 19 infection whose room air saturation is <93% .

Exclusion criteria

Exclusion criteria: 1. Patients with multi organ failure , Shock , DIC . 2. Patients with complicated COVID 19 infection . 3. Respiratory failure due to other causes such as head injury , CNS infection , DKA, severe electrolyte disturbances, neuromuscular diseases . 4. Past history of COPD , bronchial asthma . 5. Patients with cardiac disease . 6 . Patients with chronic kidney disease on hemodialysis .

Design outcomes

Secondary

MeasureTime frame
Duration of hospital stay Lower death rate Decrease in laboratory markers Lower mortality rateTimepoint: 28 days—

Primary

MeasureTime frame
Mortality at day 14 and 28 No.of patients requiring invasive ventilation No. Of icu days and hospital Incidence of secondary infectionTimepoint: Mortality at day 14 and 28 No.of patients requiring invasive ventilation No. Of icu days and hospital Incidence of secondary infection—

Countries

India

Contacts

Public ContactDr Vijaykumar H N

BMCRI

Vijay.bmc.ccm@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026